26 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
4 Oct 21
Report of Foreign Private Issuer
8:00am
2014-2019. Control patients were matched by age, gender, severity of the septic condition reflected by Sequential Organ Failure Assessment (SOFA) score … . The study subjects were also compared to historical controls hospitalized in the ICU, matched by age, gender, SOFA score, and infection source.
ABOUT
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
18 Mar 20
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
8:26am
, with 37 patients who were matched controls (matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection source) who received … hospitalized in the ICU, matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection source.
Sepsis is defined as a life
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
hospital from 2014-2019. Control patients were matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection source. The clinical … compared to historical controls hospitalized in the ICU, matched by age, gender, SOFA score, and infection source.
ABOUT SEPSIS
Sepsis is defined
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
28 May 20
Report of Foreign Private Issuer
9:25am
were followed for 28 days. The study subjects were also compared to historical controls hospitalized in the ICU, matched by age, gender, Sequential
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
2 Aug 23
Report of Foreign Private Issuer
8:05am
to a mortality rate of 3.8%−8.9% for age- and gender-severe COVID-19-matched patients, and 39%−55% for critical patients.
Average duration
6-K
EX-99.2
npbv 35g13
27 Oct 15
Current report (foreign)
12:00am
6-K
EX-99.1
z0bwqz5kjrk0py3ass
3 Nov 20
Current report (foreign)
9:14am
6-K
EX-99.1
htgmnig8x1ksji5ddw8
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
hay3 ms66s3b5ik
19 Feb 19
Asset Purchase Agreement
4:57pm
6-K
EX-99.1
yx8 7n3a0
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
6-K
EX-99.1
ij2fpfhvvkxzt
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
6-K
EX-99.2
gmf0z pzv2h1
19 Nov 18
Agreement and Plan of Merger
4:34pm
424B5
xhwvtydcg28dzp07zg
9 Feb 21
Prospectus supplement for primary offering
4:56pm
424B5
q6v3bv2ijmvzk
10 Feb 21
Prospectus supplement for primary offering
5:22pm
20-F
swh51hunf9sd
31 Mar 15
Annual report (foreign)
12:00am